490 related articles for article (PubMed ID: 27639806)
1. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
Tsai CF; Chen MH; Wang YP; Chu CJ; Huang YH; Lin HC; Hou MC; Lee FY; Su TP; Lu CL
Gastroenterology; 2017 Jan; 152(1):134-141. PubMed ID: 27639806
[TBL] [Abstract][Full Text] [Related]
2. Proton Pump Inhibitors Are Associated with Increased Risk of Psoriasis: A Nationwide Nested Case-Control Study.
Li CY; Dai YX; Chang YT; Bai YM; Tsai SJ; Chen TJ; Chen MH
Dermatology; 2021; 237(6):884-890. PubMed ID: 34474411
[TBL] [Abstract][Full Text] [Related]
3. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Leonard CE; Bilker WB; Brensinger CM; Flockhart DA; Freeman CP; Kasner SE; Kimmel SE; Hennessy S
Stroke; 2015 Mar; 46(3):722-31. PubMed ID: 25657176
[TBL] [Abstract][Full Text] [Related]
4. Safe use of proton pump inhibitors in patients with cirrhosis.
Weersink RA; Bouma M; Burger DM; Drenth JPH; Harkes-Idzinga SF; Hunfeld NGM; Metselaar HJ; Monster-Simons MH; van Putten SAW; Taxis K; Borgsteede SD
Br J Clin Pharmacol; 2018 Aug; 84(8):1806-1820. PubMed ID: 29688583
[TBL] [Abstract][Full Text] [Related]
5. Proton-pump inhibitors are associated with an increased risk of asthma: A nationwide nested case-control study.
Wang WT; Li CY; Chang YT; Bai YM; Tsai SJ; Chen TJ; Chiou SH; Chen MH
Allergy Asthma Proc; 2023 Sep; 44(5):345-353. PubMed ID: 37641222
[No Abstract] [Full Text] [Related]
6. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis.
De Roza MA; Kai L; Kam JW; Chan YH; Kwek A; Ang TL; Hsiang JC
World J Gastroenterol; 2019 Sep; 25(33):4933-4944. PubMed ID: 31543684
[TBL] [Abstract][Full Text] [Related]
7. Effect of proton pump inhibitors in hospitalization on mortality of patients with hepatic encephalopathy and cirrhosis but no active gastrointestinal bleeding.
Hung TH; Lee HF; Tseng CW; Tsai CC; Tsai CC
Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):353-359. PubMed ID: 29551615
[TBL] [Abstract][Full Text] [Related]
8. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites.
Dam G; Vilstrup H; Watson H; Jepsen P
Hepatology; 2016 Oct; 64(4):1265-72. PubMed ID: 27474889
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
11. Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study).
Lu B; Zhang L; Wang J; Wang B; Zou X; Fei G; Chen D; Wang X; Wu B; Zou D
J Gastroenterol Hepatol; 2018 Oct; 33(10):1722-1727. PubMed ID: 29575167
[TBL] [Abstract][Full Text] [Related]
12. Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis.
Tantai XX; Yang LB; Wei ZC; Xiao CL; Chen LR; Wang JH; Liu N
World J Gastroenterol; 2019 Jun; 25(21):2683-2698. PubMed ID: 31210719
[TBL] [Abstract][Full Text] [Related]
13. Proton Pump Inhibitor Exposure and Acute Myocardial Infarction Risk: A Nested Cohort Study.
Tseng HJ; Cheng CM; Tsai SJ; Lin WC; Bai YM; Tsai CF; Su TP; Li CT; Chen TJ; Chen MH
Cardiovasc Toxicol; 2021 Jun; 21(6):444-450. PubMed ID: 33625647
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Li MJ; Li Q; Sun M; Liu LQ
Medicine (Baltimore); 2017 Sep; 96(39):e8120. PubMed ID: 28953640
[TBL] [Abstract][Full Text] [Related]
15. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
[TBL] [Abstract][Full Text] [Related]
16. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
17. Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis.
Nardelli S; Gioia S; Ridola L; Farcomeni A; Merli M; Riggio O
Hepatology; 2019 Aug; 70(2):640-649. PubMed ID: 30289992
[TBL] [Abstract][Full Text] [Related]
18. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
Clark DW; Strandell J
Eur J Clin Pharmacol; 2006 Jun; 62(6):473-9. PubMed ID: 16758264
[TBL] [Abstract][Full Text] [Related]
19. The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors: A multicenter retrospective study in Japan.
Sakamaki A; Kamimura K; Yokoo T; Osaki A; Yoshikawa S; Arao Y; Setsu T; Kamimura H; Waguri N; Takeuchi M; Funakoshi K; Terai S
Medicine (Baltimore); 2021 Aug; 100(32):e26902. PubMed ID: 34397919
[TBL] [Abstract][Full Text] [Related]
20. Impact of proton pump inhibitors on cytochrome P450 activity assessed by
Rocco A; Compare D; Sgamato C; Coccoli P; Chiodini P; Nardone G
Aliment Pharmacol Ther; 2021 Mar; 53(5):608-615. PubMed ID: 33368499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
